Evidence map›Paper›PMID 35441784›Full record

ArticlePediatric blood & cancer2022

Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.

Shahab Asgharzadeh, Araz Marachelian, Judith G Villablanca, Wei Yao Liu, Rebekah Kennedy, Richard Sposto, Arlene Naranjo, Sheena Tenney, Alice L Yu, M Fevzi Ozkaynak and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. [Single-center application and analysis of neuroblastoma marker detection in childhood neuroblastoma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Shahab AsgharzadehChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.
Araz MarachelianChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.ORCID 0000-0003-3857-4782
Judith G VillablancaChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.ORCID 0000-0002-7174-669X
Wei Yao LiuChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.
Rebekah KennedyChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.
Richard SpostoChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.
Arlene NaranjoChildren's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida.
Sheena TenneyChildren's Oncology Group Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, Florida.
Alice L YuRady Children's Hospital, Department of Pediatrics, University of California San Diego, San Diego, California.
M Fevzi OzkaynakNew York Medical College, Section of Hematology-Oncology and Bone Marrow Transplantation, Valhalla, New York.
Paul M SondelUniversity of Wisconsin, Departments of Pediatrics, Human Oncology and Genetics, University of Wisconsin, Madison, Wisconsin.
Julie R ParkSeattle Children's Hospital, Department of Hematology-Oncology and University of Washington, Seattle, Washington.
Robert C SeegerChildren's Hospital Los Angeles and The Saban Research Institute, Los Angeles, California.
University of Southern California · USChildren's Hospital of Los Angeles · USChildren's Oncology Group · CHChang Gung University · TWNew York Medical College · USSeattle Children's Hospital · USUniversity of Wisconsin–Madison · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Molecular Diagnostics for Risk Stratification and Monitoring of NeuroblastomaR01CA182633 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ASGHARZADEH, SHAHAB, SEEGER, ROBERT CHARLES · 2014 to 2016
$2.0M
Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts OutcomeR33CA152809 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI SEEGER, ROBERT CHARLES · 2010 to 2012
$1.3M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA182633NCI NIH HHS R33 CA152809NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

backgroundMinimal disease quantification may predict event-free survival (EFS) and overall survival (OS).

methodsWe evaluated mRNA expression of five neuroblastoma-associated genes (NB5 assay) in bone marrows (BM) of patients with newly diagnosed high-risk neuroblastoma who received consistent immunotherapy. mRNA expression of CHGA, DCX, DDC, PHOX2B, and TH genes in BM of 479 patients enrolled on the immunotherapy arm of Children's Oncology Group trials ANBL0032 and ANBL0931 was evaluated using real-time polymerase chain reaction (PCR)-based TaqMan low-density array. Results from end-consolidation and end-therapy were analyzed for association with five-year EFS/OS and patient and tumor characteristics. Tests of statistical significance were two-sided.

resultsNB5 assay detected neuroblastoma-related mRNA in 222 of 286 (77.6%) of BMs obtained at end-consolidation and 188 of 304 (61.8%) at end-therapy. Any mRNA level detected in end-therapy BM correlated with significantly worse EFS (57% [49.6%-63.7%] vs 73.0% [63.5%-80.4%]; P = 0.005), but not OS. Analysis limited to patients in complete response at end-therapy still found a significant difference in EFS with detectable versus not detectable NB5 assay results (58.9% [49.5%-67.1%] vs 76.6% [66.1%-84.2%]; P = 0.01). End-consolidation results did not correlate with EFS or OS. Multivariable analysis determined end-therapy NB5 assay BM results (P = 0.02), age at diagnosis (P = 0.002), and preconsolidation response (P = 0.02) were significantly associated with EFS independent of other clinical and biological parameters evaluated, including end-therapy response.

conclusionsIf further validated in additional patient cohorts, the NB5 assay's ability to independently predict EFS from end-therapy could improve patient stratification for novel maintenance therapy trials after current end-therapy to improve outcome.

Indexed as

Bone MarrowNeuroblastomaBiomarkers, TumorChildHumansInfantPrognosisRNA, MessengerBiomarkers, TumorRNA, MessengerMinimal residual diseaseneuroblastomaprognostic biomarkers

Identifiers

PMID35441784
PMCPMC9329214
OpenAlexW4224254102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.